Ergoteles LLC Athenex, Inc. Transaction History

Ergoteles LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.24 - $1.11 $62,766 - $290,294	-261,527 Reduced 61.96%	160,573 $43,000
Q2 2022 Aug 12, 2022	BUY	$0.41 - $0.91 $173,061 - $384,111	422,100 New	422,100 $173,000
Q4 2021 Feb 14, 2022	SELL	$1.36 - $2.94 $74,800 - $161,700	-55,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.97 - $4.84 $163,350 - $266,200	55,000 New	55,000 $166,000
Q4 2020 Feb 11, 2021	SELL	$11.06 - $14.01 $371,616 - $470,736	-33,600 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$10.26 - $14.55 $344,736 - $488,880	33,600 New	33,600 $407,000

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.